Rutin Therapy Role in Reducing Ulcerative Colitis Severity

Benha University

Status: Completed

Conditions: Ulcerative Colitis

Treatments: Drug: Rutin 500 MG; Diagnostic Test: fecal calprotectin; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07147842

RC 3.7.2025

Details and patient eligibility

About

Ulcerative colitis (UC) is an inflammatory bowel disease characterized by oxidative stress and recurring inflammation in the colon. The condition can become chronic, spread, and lead to other complications.

A key player in the inflammation process is the NLRP3 inflammasome. This inflammasome's expression is heightened and activated by reactive oxygen species (ROS). Its activity is influenced by various factors, including the ubiquitin system, ion channels, and gut microbiota.

Rutin, a compound found in many fruits and vegetables, has been shown to have properties that help scavenge free radicals.

Enrollment: 60 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients presenting with symptoms suggestive of IBD;
• Patients with positive microscopic mucosal changes consistent with UC.

Exclusion criteria

• Patients with the presence of recurrent ulceration after surgical treatment, malignancy, or autoimmune disorders.

Trial design

Primary purpose: Supportive Care

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 3 patient groups

Ulcerative Colitis-A (UC-A)

Active Comparator group

Description:

Patients diagnosed with active Ulcerative Colitis were assigned as group UC-A

Treatment:

Diagnostic Test: fecal calprotectin

Drug: Rutin 500 MG

Ulcerative Colitis-B (UC-B)

Active Comparator group

Description:

Patients diagnosed with remission Ulcerative Colitis were assigned as control group UC-B

Treatment:

Other: Placebo

Diagnostic Test: fecal calprotectin

Healthy Group (C)

Active Comparator group

Description:

Healthy volunteers provided samples as negative controls; and was assigned as group C

Treatment:

Diagnostic Test: fecal calprotectin